Cargando…
PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children
Background/Objectives: Relapse or refractory brain tumor in childhood continue to have a dismal prognosis in spite of developing multidisciplinary treatment. Cancer immunotherapy is newly expected as next promising treatment for highly aggressive pediatric cancer. This trial was designed to evaluate...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699127/ http://dx.doi.org/10.1093/noajnl/vdaa143.038 |
_version_ | 1783615977876881408 |
---|---|
author | Akasaki, Yasuharu Yamaoka, Masayoshi Takei, Jun Nonaka, Yuichirou Hirotsu, Tatsuya Akiyama, Masaharu Yanagisawa, Takaaki Ohashi, Touya Ida, Hiroyuki Murayama, Yuichi |
author_facet | Akasaki, Yasuharu Yamaoka, Masayoshi Takei, Jun Nonaka, Yuichirou Hirotsu, Tatsuya Akiyama, Masaharu Yanagisawa, Takaaki Ohashi, Touya Ida, Hiroyuki Murayama, Yuichi |
author_sort | Akasaki, Yasuharu |
collection | PubMed |
description | Background/Objectives: Relapse or refractory brain tumor in childhood continue to have a dismal prognosis in spite of developing multidisciplinary treatment. Cancer immunotherapy is newly expected as next promising treatment for highly aggressive pediatric cancer. This trial was designed to evaluate the safety and clinical responses to an immunotherapy with fusions of dendritic cells (DCs) and tumor cells in patients with malignant brain tumors. Design/Methods: Patients with histopathologically confirmed high-grade or recurrent brain tumor were eligible for our immunotherapy. Autologous cultured tumor cells obtained from surgical specimens were fused with autologous DCs using polyethylene glycol. The fusion cells (FC) were inoculated intradermally in the cervical region and repeated 3–10 times in each 28–84 days cycle. Toxicity, progression-free survival (PFS), and overall survival (OS) of this trial were evaluated. Results: Six patients were enrolled, three with high grade glioma and three with ependymoma. Median age at first course of immunotherapy was 10 years (range 8–25 years) and median time of follow-up from first course of immunotherapy was 13.5 months (range 3–33 months). All patients with immunotherapy were well tolerated and no adverse event without local erythema in injected site. Median progression free survival and overall survival were 18 months and 18.5 months, respectively. Conclusions: FC immunotherapy with autologous DCs and tumor cells for brain tumor in children and young adults were extremely well tolerated and encouraging. Further phase II study of FC immunotherapy is planned to improve prognosis and overcome treatment related neurological sequelae for highly malignant tumors. |
format | Online Article Text |
id | pubmed-7699127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-76991272020-12-02 PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children Akasaki, Yasuharu Yamaoka, Masayoshi Takei, Jun Nonaka, Yuichirou Hirotsu, Tatsuya Akiyama, Masaharu Yanagisawa, Takaaki Ohashi, Touya Ida, Hiroyuki Murayama, Yuichi Neurooncol Adv Supplement Abstracts Background/Objectives: Relapse or refractory brain tumor in childhood continue to have a dismal prognosis in spite of developing multidisciplinary treatment. Cancer immunotherapy is newly expected as next promising treatment for highly aggressive pediatric cancer. This trial was designed to evaluate the safety and clinical responses to an immunotherapy with fusions of dendritic cells (DCs) and tumor cells in patients with malignant brain tumors. Design/Methods: Patients with histopathologically confirmed high-grade or recurrent brain tumor were eligible for our immunotherapy. Autologous cultured tumor cells obtained from surgical specimens were fused with autologous DCs using polyethylene glycol. The fusion cells (FC) were inoculated intradermally in the cervical region and repeated 3–10 times in each 28–84 days cycle. Toxicity, progression-free survival (PFS), and overall survival (OS) of this trial were evaluated. Results: Six patients were enrolled, three with high grade glioma and three with ependymoma. Median age at first course of immunotherapy was 10 years (range 8–25 years) and median time of follow-up from first course of immunotherapy was 13.5 months (range 3–33 months). All patients with immunotherapy were well tolerated and no adverse event without local erythema in injected site. Median progression free survival and overall survival were 18 months and 18.5 months, respectively. Conclusions: FC immunotherapy with autologous DCs and tumor cells for brain tumor in children and young adults were extremely well tolerated and encouraging. Further phase II study of FC immunotherapy is planned to improve prognosis and overcome treatment related neurological sequelae for highly malignant tumors. Oxford University Press 2020-11-28 /pmc/articles/PMC7699127/ http://dx.doi.org/10.1093/noajnl/vdaa143.038 Text en © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Supplement Abstracts Akasaki, Yasuharu Yamaoka, Masayoshi Takei, Jun Nonaka, Yuichirou Hirotsu, Tatsuya Akiyama, Masaharu Yanagisawa, Takaaki Ohashi, Touya Ida, Hiroyuki Murayama, Yuichi PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children |
title | PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children |
title_full | PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children |
title_fullStr | PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children |
title_full_unstemmed | PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children |
title_short | PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children |
title_sort | pedt-03 a clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699127/ http://dx.doi.org/10.1093/noajnl/vdaa143.038 |
work_keys_str_mv | AT akasakiyasuharu pedt03aclinicaltrialofdendriticcellbasedimmunotherapyforrefractorybraintumorsinchildren AT yamaokamasayoshi pedt03aclinicaltrialofdendriticcellbasedimmunotherapyforrefractorybraintumorsinchildren AT takeijun pedt03aclinicaltrialofdendriticcellbasedimmunotherapyforrefractorybraintumorsinchildren AT nonakayuichirou pedt03aclinicaltrialofdendriticcellbasedimmunotherapyforrefractorybraintumorsinchildren AT hirotsutatsuya pedt03aclinicaltrialofdendriticcellbasedimmunotherapyforrefractorybraintumorsinchildren AT akiyamamasaharu pedt03aclinicaltrialofdendriticcellbasedimmunotherapyforrefractorybraintumorsinchildren AT yanagisawatakaaki pedt03aclinicaltrialofdendriticcellbasedimmunotherapyforrefractorybraintumorsinchildren AT ohashitouya pedt03aclinicaltrialofdendriticcellbasedimmunotherapyforrefractorybraintumorsinchildren AT idahiroyuki pedt03aclinicaltrialofdendriticcellbasedimmunotherapyforrefractorybraintumorsinchildren AT murayamayuichi pedt03aclinicaltrialofdendriticcellbasedimmunotherapyforrefractorybraintumorsinchildren |